




Searching News Database: Alzheimer's
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 9 Sep 2024
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
HSMN NewsFeed - 26 Aug 2024
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
HSMN NewsFeed - 24 Jul 2024
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
HSMN NewsFeed - 10 Jun 2024
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems
HSMN NewsFeed - 14 Feb 2024
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
HSMN NewsFeed - 4 Jan 2024
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect(TM)
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect(TM)
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 11 Oct 2023
Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease
Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
HSMN NewsFeed - 11 Jul 2022
DiamiR Biosciences Appoints Alidad Mireskandari, Ph.D., MBA, as Chief Executive Officer
DiamiR Biosciences Appoints Alidad Mireskandari, Ph.D., MBA, as Chief Executive Officer
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
HSMN NewsFeed - 24 Jun 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
HSMN NewsFeed - 3 Jun 2021
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
HSMN NewsFeed - 9 Nov 2020
DTx Pharma Announces Appointment of Denise Bevers as Chief Operating Officer
DTx Pharma Announces Appointment of Denise Bevers as Chief Operating Officer
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
HSMN NewsFeed - 2 Mar 2020
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
HSMN NewsFeed - 1 May 2019
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
HSMN NewsFeed - 11 Dec 2018
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
Avanir Pharmaceuticals Announces Termination of License Agreement with Optinose for ONZETRA(R) Xsail(R)
HSMN NewsFeed - 1 Nov 2018
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
HSMN NewsFeed - 23 Aug 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
HSMN NewsFeed - 9 Jul 2018
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HSMN NewsFeed - 12 Jun 2018
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 18 May 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
HSMN NewsFeed - 12 Apr 2018
FDA Permits Marketing of IDx-DR for Automated Detection of Diabetic Retinopathy in Primary Care
FDA Permits Marketing of IDx-DR for Automated Detection of Diabetic Retinopathy in Primary Care
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
HSMN NewsFeed - 30 Aug 2017
PhRMA Announces Dr. Richard Moscicki as New Chief Medical Officer and Executive Vice President
PhRMA Announces Dr. Richard Moscicki as New Chief Medical Officer and Executive Vice President
HSMN NewsFeed - 12 Jul 2017
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
HSMN NewsFeed - 27 Jun 2017
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
Mitoconix Bio Raises $20 Million in Series A Funding to Develop Neurodegenerative Disease Therapies
HSMN NewsFeed - 23 Jun 2017
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
HSMN NewsFeed - 9 Dec 2016
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
HSMN NewsFeed - 28 Oct 2016
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 27 Jul 2016
John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 12 May 2016
Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
HSMN NewsFeed - 16 Feb 2016
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
HSMN NewsFeed - 2 Dec 2015
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
HSMN NewsFeed - 21 Oct 2015
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
HSMN NewsFeed - 8 Apr 2015
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
HSMN NewsFeed - 23 Oct 2014
AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. as Chief Executive Officer
AbVitro Inc. Appoints Jeffrey M. Ostrove, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
HSMN NewsFeed - 23 Jun 2014
Barry Lederman Appointed Vice President and Chief Financial Officer of Eisai Inc.
Barry Lederman Appointed Vice President and Chief Financial Officer of Eisai Inc.
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 8 May 2014
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
HSMN NewsFeed - 18 Feb 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 16 Dec 2013
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
HSMN NewsFeed - 7 May 2013
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
HSMN NewsFeed - 15 Nov 2012
Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer
Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer
HSMN NewsFeed - 14 Nov 2012
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
HSMN NewsFeed - 16 Oct 2012
BioAdvance Expands Team to Support Portfolio Companies and New Investments
BioAdvance Expands Team to Support Portfolio Companies and New Investments
HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
HSMN NewsFeed - 22 Feb 2012
Integrated Diagnostics(R) Secures $10 Million Third Tranche of Series A Financing
Integrated Diagnostics(R) Secures $10 Million Third Tranche of Series A Financing
HSMN NewsFeed - 16 Feb 2012
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
HSMN NewsFeed - 10 Dec 2011
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
HSMN NewsFeed - 16 Aug 2011
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
HSMN NewsFeed - 9 May 2011
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
HSMN NewsFeed - 12 Apr 2011
DARA BioSciences Reports That SurgiVision Has Completed a Commercial Alliance With Brainlab AG
DARA BioSciences Reports That SurgiVision Has Completed a Commercial Alliance With Brainlab AG
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
HSMN NewsFeed - 24 Mar 2011
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
HSMN NewsFeed - 8 Feb 2011
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic Imaging
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic Imaging
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 19 Jan 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
HSMN NewsFeed - 14 Jan 2011
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
HSMN NewsFeed - 16 Sep 2010
FluoroPharma Inc. Appoints Mr. Thijs Spoor as Chief Executive Officer and Director
FluoroPharma Inc. Appoints Mr. Thijs Spoor as Chief Executive Officer and Director
HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
HSMN NewsFeed - 16 Aug 2010
Curaxis Pharmaceutical Corp Elects Dr. Bert A. Spilker to Board of Directors
Curaxis Pharmaceutical Corp Elects Dr. Bert A. Spilker to Board of Directors
HSMN NewsFeed - 11 Aug 2010
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
HSMN NewsFeed - 22 Jul 2010
Integrated Diagnostics Secures $10 Million Second Tranche of Series A Financing
Integrated Diagnostics Secures $10 Million Second Tranche of Series A Financing
HSMN NewsFeed - 13 Jul 2010
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
HSMN NewsFeed - 23 Mar 2010
Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
Once-Daily MIRAPEX ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
HSMN NewsFeed - 8 Mar 2010
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
HSMN NewsFeed - 22 Feb 2010
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease
HSMN NewsFeed - 9 Feb 2010
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
HSMN NewsFeed - 9 Feb 2010
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
HSMN NewsFeed - 13 Jan 2010
Population Diagnostics, Inc. Appoints Dr. Peggy Eis as Chief Technology Officer
Population Diagnostics, Inc. Appoints Dr. Peggy Eis as Chief Technology Officer
HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
HSMN NewsFeed - 18 Mar 2009
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
HSMN NewsFeed - 10 Mar 2009
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
HSMN NewsFeed - 6 Feb 2009
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
HSMN NewsFeed - 4 Feb 2009
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
HSMN NewsFeed - 8 Jan 2009
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
HSMN NewsFeed - 16 Dec 2008
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
HSMN NewsFeed - 28 Oct 2008
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer’s Disease Study
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer’s Disease Study
HSMN NewsFeed - 17 Sep 2008
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
HSMN NewsFeed - 12 Sep 2008
Power3 Medical Products, Inc. Appoints Helen Park as Interim Chief Executive Officer
Power3 Medical Products, Inc. Appoints Helen Park as Interim Chief Executive Officer
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
HSMN NewsFeed - 24 Jul 2008
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
HSMN NewsFeed - 29 May 2008
Aspect Medical Systems Announces U.S. Sales Force Expansion Plan and Reaffirms Q2 Financial Guidance
Aspect Medical Systems Announces U.S. Sales Force Expansion Plan and Reaffirms Q2 Financial Guidance
HSMN NewsFeed - 14 May 2008
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
HSMN NewsFeed - 31 Mar 2008
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
HSMN NewsFeed - 13 Mar 2008
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
HSMN NewsFeed - 12 Mar 2008
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 20 Feb 2008
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
HSMN NewsFeed - 31 Jan 2008
Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments
Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments
HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
HSMN NewsFeed - 22 Jan 2008
Samaritan Hires Expert Marketing Specialist to Build Up Southeast Europe Sales
Samaritan Hires Expert Marketing Specialist to Build Up Southeast Europe Sales
HSMN NewsFeed - 28 Dec 2007
Transition Therapeutics Announces Appointment of Vice-President of Business Development
Transition Therapeutics Announces Appointment of Vice-President of Business Development
HSMN NewsFeed - 27 Dec 2007
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 13 Dec 2007
Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
Forest Laboratories Receives Notification of ANDA Filings for Generic Equivalents of Namenda(R)
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem announces important initiatives to provide medical and health benefits to patients
HSMN NewsFeed - 22 Oct 2007
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
HSMN NewsFeed - 10 Oct 2007
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
HSMN NewsFeed - 25 Sep 2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
HSMN NewsFeed - 30 Aug 2007
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
HSMN NewsFeed - 28 Aug 2007
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 14 Aug 2007
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 31 Jul 2007
Neuren to Obtain Late Stage Compound Through Hamilton Pharmaceuticals Acquisition
Neuren to Obtain Late Stage Compound Through Hamilton Pharmaceuticals Acquisition
HSMN NewsFeed - 24 Jul 2007
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
HSMN NewsFeed - 18 Jul 2007
FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease
HSMN NewsFeed - 17 Jul 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
HSMN NewsFeed - 12 Jul 2007
Resverlogix Corp.: Dr. Roger Newton, Co-Discoverer of Lipitor(R), Commences his Board of Directors Position
Resverlogix Corp.: Dr. Roger Newton, Co-Discoverer of Lipitor(R), Commences his Board of Directors Position
HSMN NewsFeed - 27 Jun 2007
Aspect Medical Systems Receives FDA Clearance for BIS View(TM) Monitoring System
Aspect Medical Systems Receives FDA Clearance for BIS View(TM) Monitoring System
HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
HSMN NewsFeed - 19 Jun 2007
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
HSMN NewsFeed - 18 Jun 2007
Gene Logic Collaboration Reveals Genomic Predictors of Parkinson's Disease
Gene Logic Collaboration Reveals Genomic Predictors of Parkinson's Disease
HSMN NewsFeed - 18 Jun 2007
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
HSMN NewsFeed - 18 Jun 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
Additional items found! 500

Members Archive contains
500 additional stories matching:
Alzheimer's
(Password required)
Alzheimer's
(Password required)